Organisation paid for research Program year 2025 Source: CMS Open Payments

Community Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$480,127

70 payments

Through program year 2025, Community Clinical Trials is reported as receiving $480,127 in research payments, across 70 payments.

By program year

1 row
Year Kind Amount Payments
2025 Research $480,127 70

Breakdown

Who paid Research payments · program year 2025
  1. AstraZeneca Pharmaceuticals LP $207,551 4 payments
  2. Aveo Pharmaceuticals, Inc. $155,602 60 payments
  3. Pfizer Inc. $70,773 2 payments
  4. Amgen Inc. $24,952 1 payment
  5. GlaxoSmithKline, LLC. $21,250 3 payments
Studies the money was for Research payments · program year 2025
  1. A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels $155,602 60 payments
  2. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $77,474 1 payment
  3. An Openlabel Randomized Controlled Phase 3 Study of Sigvotatug Vedotin in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As Firstline Treatment in Participants With Pdl1 High 50 of Tumor Cells Expressing Pdl1 Locally Advanced Unresectable Or Metastatic Nonsmall Cell Lung Cancer Be6a Lung02 $70,773 2 payments
  4. A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 $49,617 1 payment
  5. Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer $44,521 1 payment
  6. A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) $35,939 1 payment
  7. A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202 $24,952 1 payment
  8. A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Admi $21,250 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record